Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CCR1 | P32246 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | CCR8 | P51685 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.44 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.41 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.39 |
| ▸ | CBFB | Q13951 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29543410 | 1.00 | KDM4E (0.44) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL367648 | 0.84 | KDM4E (0.42) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL26237923 | 0.83 | KDM4E (0.41) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL2356330 | 0.83 | KDM4E (0.41) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL2358851 | 0.83 | KDM4E (0.41) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL30194796 | 0.81 | — | — | |
| SCHEMBL10762482 | 0.81 | KDM4E (0.51) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL28432131 | 0.81 | CHRM5 (0.53) | KDM4ECYP1A2BLMTLR7RUNX1 | |
| SCHEMBL5378152 | 0.79 | KDM4E (0.38) | KDM4ELMNACCR1CCR5CCR8 | |
| Hydrochloric Acid SCHEMBL5573936 | 0.78 | KDM4E (0.37) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246932-A1 | ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-07-25 | — | — | US | claimed |
| EP-4232153-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | Evotec International GmbH (DE) | 2023-08-30 | — | — | EP | claimed |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | claimed |
| WO-2022084446-A1 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY | EVOTEC INTERNATIONAL GMBH (DE) | 2022-04-28 | — | — | WO | claimed |
| EP-0204535-B1 | N-FLUOROPYRIDINIUM SALT AND PROCESS FOR PREPARING SAME | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-08-19 | — | — | EP | claimed |
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2026-05-14 | — | — | US | disclosed |
| EP-4735431-A2 | MK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | NOVARTIS PHARMA AG (CH) | 2025-12-23 | — | — | US | disclosed |
| EP-4318630-B1 | NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS SECONDARY BATTERY | ASAHI CHEMICAL IND (JP) | 2025-10-22 | — | — | EP | disclosed |
| EP-3487856-B1 | SUBSTITUTED DIAZAHETERO-BICYCLIC COMPOUNDS AND THEIR USE | BAYER AG (DE) | 2025-01-22 | — | — | EP | disclosed |
| WO-2025011533-A1 | CARBOXYLIC ACID COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海宇道生物技术有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-12199280-B2 | Non-aqueous secondary battery and non-aqueous electrolyte | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2025-01-14 | — | — | US | disclosed |
| CN-1184405-A | Insecticidal N -(substituted arylmethyl) -4 -[bis (substituted phenyl or pyridyl) methyl] piperidines | FMC CORP (US) | 1998-06-10 | — | — | CN | disclosed |
| US-RE35177-E | N-fluoropyridinium salt and process for preparing same | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1996-03-12 | — | — | US | disclosed |
| EP-0494770-B1 | Method for preparing N-fluoropyridinium salts | ONODA CEMENT CO LTD (JP) | 1995-05-10 | — | — | EP | disclosed |
| US-5336772-A | Reacting pyridine compound, fluorine and Bronsted acid in specified ratios | ONODA CEMENT CO., LTD. (JP) | 1994-08-09 | — | — | US | disclosed |
| EP-0204535-B1 | N-FLUOROPYRIDINIUM SALT AND PROCESS FOR PREPARING SAME | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-08-19 | — | — | EP | disclosed |
| EP-0494770-A1 | Method for preparing N-fluoropyridinium salts | ONODA CEMENT COMPANY, LTD. (JP) | 1992-07-15 | — | — | EP | disclosed |
| US-4996320-A | Thyroid inhibitors | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1991-02-26 | — | — | US | disclosed |
| EP-0204535-A1 | N-fluoropyridinium salt and process for preparing same | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1986-12-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132109-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, IRF3, CGAS | KDM4E 4580/4885LMNA 208/4885CCR1 610/4885 |
| US-20240246932-A1 | ARYL 3-OXOPIPERAZINE CARBOXAMIDES AND HETEROARYL 3-OXOPIPERAZINE CARBOXAMIDES AS NAV1.8 INHIBITORS | TRPV1, SCN8A, SCN2A | KDM4E 3149/4885LMNA 4025/4885CCR1 962/4885 |
| US-20230227429-A1 | SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP1 | KDM4E 1464/4885LMNA 884/4885CCR1 4023/4885 |
| US-12503436-B2 | Compounds and compositions for treating conditions associated with STING activity | STING1, CGAS, IRF3 | KDM4E 3761/4885LMNA 2339/4885CCR1 2064/4885 |
| US-12199280-B2 | Non-aqueous secondary battery and non-aqueous electrolyte | CLK2, TYK2, CLK3 | KDM4E 1884/4885LMNA 248/4885CCR1 2429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.